vimarsana.com

Latest Breaking News On - Daniel stauder - Page 1 : vimarsana.com

Avanos Medical, Inc (NYSE:AVNS) Q1 2024 Earnings Call Transcript

LeMaitre Vascular, Inc (NASDAQ:LMAT) Q4 2023 Earnings Call Transcript

An atrial fibrillation device maker has 70% upside, JMP Securities says

Analyst Daniel Stauder initiated coverage of the stock with an outperform rating and $60 price target, implying shares could soar by almost 70%.

Potential Turnaround Ahead for Nevro: Q2 Earnings, Guidance Lag Wall Street Estimates - Nevro (NYSE:NVRO)

Pain management company Nevro Corp (NASDAQ: NVRO) reported Q2 FY23 revenue of $108.8 million, up 4% Y/Y, missing the management guidance of $110 million-$112 million and 

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.